Novo Nordisk Shares Jump After U.S. Approves Weight-Loss Pill

Post by : Saif Nasser

Shares of Danish drugmaker Novo Nordisk rose sharply on Tuesday after U.S. health regulators approved its new weight-loss pill. The company’s stock jumped about 7.5% in early trading, reflecting strong investor confidence in the future of oral treatments for obesity.

The approval by the U.S. Food and Drug Administration gives Novo Nordisk an early advantage in the fast-growing weight-loss drug market. Until now, most effective obesity treatments have required weekly injections, which many patients find uncomfortable or inconvenient. A pill option is expected to attract people who prefer an easier way to manage weight loss.

Novo Nordisk is best known for Wegovy, its injectable weight-loss drug launched in 2021. While demand for Wegovy was very high, the company struggled at first to produce enough supply. This time, Novo Nordisk says it is better prepared. Company executives have stated that they have enough pills ready and plan to push strongly for a smooth rollout in the United States.

The company has recently faced pressure as it lost market share to rivals, especially U.S. drugmaker Eli Lilly. Lilly’s injectable weight-loss drug, Zepbound, has gained popularity and now leads in weekly prescriptions in the U.S. Novo Nordisk’s share price had fallen more than 50% earlier this year, making the FDA approval a much-needed boost.

Market analysts believe the pill gives Novo Nordisk a short-term lead. Many patients are expected to choose pills over injections, especially those who feel uneasy about needles. However, experts also warn that this advantage may not last long. Eli Lilly is developing its own oral weight-loss drug, which could receive approval as early as 2026.

Some healthcare investors say oral drugs could grow the overall market instead of replacing injections. Many adults delay treatment simply because they do not want to inject themselves. At the same time, analysts point out that pills may not be as powerful as injectable drugs, which could limit how effective they are for certain patients.

Financial forecasts for the new pill are strong. Some analysts expect global annual sales to reach billions of dollars, helping Novo Nordisk balance possible challenges ahead, such as lower drug prices and rising competition in 2026.

On Tuesday, Novo Nordisk shares were among the biggest gainers in European markets, while Eli Lilly’s shares slipped slightly. The approval highlights how competitive and valuable the obesity treatment market has become, as drugmakers race to offer safer, easier, and more effective options for millions of patients worldwide.